Step down of inhaler therapy in well controlled asthmatics with ICS/LABA, Symbicort Turbuhaler.

Step down of inhaler therapy in well controlled asthmatics with ICS/LABA, Symbicort Turbuhaler. - Step Down Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005780

Enrollment

120

Registered

2011-06-14

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

Inhalation of low-dose of budesonide / formoterol combination (Symbicort turbuhaler, one inhalatiom twice daily) Inhalation of medium-dose of budesonide (Pulmicort 200 turbuhaler, two inhalatiom twic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Well-controlled asthmatics with inhalation of medium-dose of budesonide / formoterol combination (Symbicort turbuhaler two inhalatiom twice daily) for twelve weeks

Exclusion criteria

Exclusion criteria: History of hypersensitivity to budesonide or formoterol Use of systemic corticosteroids or anti-IgE antibody

Design outcomes

Primary

Measure	Time frame
ACQ-5 (asthma control Questionnaire-5) 12 week after step down therapy	—

Secondary

Measure	Time frame
number of puffs in short acting beta2-agonist use pulmonary function PEFR Exhaled nitric oxide withdrawal due to exacerbation and side effects	—

Countries

Japan

Contacts

Public ContactKazuhiko Fujii

Kumamoto University Hospital Respiratory Medicine

kokyukinaika@fc.kuh.kumamoto-u.ac.jp096-373-5012

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026